Leukocyte L1 Antigen Complex
"Leukocyte L1 Antigen Complex" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A member of the S-100 protein family that is present at high levels in the blood and interstitial fluid in several infectious, inflammatory, and malignant disorders, including rheumatoid arthritis, inflammatory bowel disease, and cystic fibrosis. It is a complex of a light chain (CALGRANULIN A) and a heavy chain (CALGRANULIN B). L1 binds calcium through an EF-hand motif, and has been shown to possess antimicrobial activity.
|Leukocyte L1 Antigen Complex
- Leukocyte L1 Antigen Complex
- Calcium-Binding Myeloid Protein P8,14
- Calcium Binding Myeloid Protein P8,14
- Migratory Inhibitory Factor-Related Protein MRP
- Migratory Inhibitory Factor Related Protein MRP
- Myelomonocytic Antigen L1
- Antigen L1, Myelomonocytic
- L1 Antigen
- Antigen, L1
- 27E10 Antigen
- Antigen, 27E10
- Leukocyte L1 Protein
- L1 Protein, Leukocyte
Below are MeSH descriptors whose meaning is more general than "Leukocyte L1 Antigen Complex".
Below are MeSH descriptors whose meaning is more specific than "Leukocyte L1 Antigen Complex".
This graph shows the total number of publications written about "Leukocyte L1 Antigen Complex" by people in this website by year, and whether "Leukocyte L1 Antigen Complex" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Leukocyte L1 Antigen Complex" by people in Profiles.
Patient-Reported Outcomes Correlate With Microbial Community Composition Independent of Mucosal Inflammation in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis. 2023 02 01; 29(2):286-296.
A Prospective Trial with Long Term Follow-up of Patients With Severe, Steroid-Resistant Ulcerative Colitis Who Received Induction Therapy With Cyclosporine and Were Maintained With Vedolizumab. Inflamm Bowel Dis. 2022 10 03; 28(10):1549-1554.
CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease. Gastroenterology. 2022 10; 163(4):950-964.
Molecular Basis of Ca(II)-Induced Tetramerization and Transition-Metal Sequestration in Human Calprotectin. J Am Chem Soc. 2021 11 03; 143(43):18073-18090.
Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study. J Crohns Colitis. 2021 Jul 05; 15(7):1120-1129.
Fecal Calprotectin Is Highly Effective to Detect Endoscopic Ulcerations in Crohn's Disease Regardless of Disease Location. Inflamm Bowel Dis. 2021 06 15; 27(7):1008-1016.
International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. United European Gastroenterol J. 2021 05; 9(4):451-460.
Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Na?ve Crohn's Disease. Clin Gastroenterol Hepatol. 2022 07; 20(7):1579-1587.e2.
Ulcerative Colitis in Adults. JAMA. 2020 Sep 22; 324(12):1205-1206.
Diagnostic Accuracy of Fecal Calprotectin Concentration in Evaluating Therapeutic Outcomes of Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2021 11; 19(11):2333-2342.